Return To The Previous Page
Buy a Package
Number Of Visible Items Remaining : 3 Item

Approach to insulin therapy for cystic fibrosis-related diabetes

Approach to insulin therapy for cystic fibrosis-related diabetes
Indication Suggested starting doses for insulin
Patient with high blood glucose on OGTT, or random hyperglycemia with worsening lung function and weight loss

Long-acting (basal) insulin 0.1 units/kg every morning. For patients on glucocorticoids, use starting dose of insulin 0.2 units/kg.

Increase dose by increments of 0.1 units/kg, aiming for postprandial blood glucose <140 mg/dL (7.8 mmol/L), without hypoglycemia.
Inability to reach glycemic targets on basal insulin alone Add prandial insulin (0.5 units rapid-acting insulin for each 15 g carbohydrate, given just prior to the meal), in addition to basal insulin.
Hyperglycemia in hospital for infection or pulmonary exacerbation, or patient on glucocorticoids Increase starting dose of basal insulin to 0.2 units/kg. Most patients also require prandial insulin during intercurrent infections.
High blood glucose in patient on overnight enteral feeds Basal insulin (detemir or glargine) 0.1 units/kg at bedtime, in combination with a rapid-acting or regular insulin*.
Difficulties reaching glycemic goals with above regimens, and/or desire for more convenient or physiologic insulin replacement Continuous subcutaneous insulin infusion (insulin pump).

OGTT: oral glucose tolerance test; A1C: hemoglobin A1c (glycated hemoglobin); NPH: neutral protamine hagedorn.

* An alternative is NPH (also known as isophane insulin) given alone, but it has a very variable pharmacodynamic response compared with detemir and glargine.
Graphic 97532 Version 4.0

Do you want to add Medilib to your home screen?